CRISPR systems gave researchers a comparatively simple way to direct molecular machinery to a chosen genetic sequence. Since then, the field has expanded into several editing strategies that can cut DNA, change individual bases, regulate genes, or rewrite short stretches of sequence.
What CRISPR changed
Older genetic-engineering methods could be powerful but cumbersome. CRISPR made targeted editing easier to design and deploy in research organisms and cells. That accelerated basic research into gene function and opened new paths toward therapies, diagnostics, crop engineering, and synthetic biology.
Precision is not the same as perfection
Genome editing can still produce unintended changes, incomplete editing, mosaic outcomes, delivery problems, immune responses, or effects that depend on cell type and biological context. A technically possible edit is not automatically a safe or useful one.
Current research: CTX310 and cholesterol
On September 29, 2026, the Murphy Knowledge Project added a notable example of CRISPR moving from laboratory technique toward experimental human medicine. CTX310 is a one-time intravenous CRISPR-Cas9 treatment designed to disable ANGPTL3 in liver cells. ANGPTL3 normally helps regulate lipid metabolism, so reducing its activity can lower circulating atherogenic lipids.
MKP perspective
The most interesting part of this result is not simply the size of the cholesterol reduction. It is the possibility that a single genetic intervention could create a durable biological effect that currently requires ongoing medication for many patients. That makes CTX310 an important example of the transition from treating a biochemical measurement repeatedly to modifying one of the biological mechanisms that helps produce it.
But the distinction between promising and proven matters. This study involved only 15 people, had no placebo control, and measured lipid biomarkers rather than reductions in heart attacks, strokes, or mortality. Gene editing is also intended to be durable, which makes long-term safety especially important. Larger and longer trials will be needed before CTX310 could be considered an established cholesterol treatment.
Why this belongs in the Knowledge Project
Genome editing sits at the intersection of chemistry, biology, medicine, agriculture, ethics, and engineering. It is a good example of why scientific literacy requires both mechanism and context: understanding what the tool can do, what evidence supports a claim, and where uncertainty remains.